AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Tracheal Aspirate sample collection
Description: Patients on a breathing machine have a breathing tube in their trachea that connects their lungs to the breathing machine. A smaller tube, called a suction catheter, will be placed through the larger tube and fluid will be gently sucked out.~Tracheal aspirate will be collected in hospital on intubated patients only (Cohorts A, B)
Study NCT06521502 — intervention group
Intervention type: PROCEDURE
Intervention: Non-bronchoscopic bronchoalveolar lavage (NBBAL)
Description: The NBBAL procedure involves putting a flexible rubber tube through the breathing tube into the airway of one of the lungs. A small amount of fluid is injected into the lung and then a gentle suction is used to collect fluid. Only patients who pass a safety screen showing that they are not at high risk for complications will have the NBBAL procedure performed.~NBBAL will be performed in hospital on intubated patients only (Cohort A)
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Participants will be contacted by email, text, and /or phone to give updates about their health. These surveys will ask questions about quality of life, mental health, return to work, and re-admission to the hospital. (Cohort A)
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Short physical performance battery
Description: At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort)~Chair Stand Test: For this test the participant will sit in a chair. They will then stand as quickly as possible without using their upper body to assist them.~Balance Test: For this test the participant will stand unsupported for 10 seconds with their feet in 3 different positions.~4-meter walk: For this test the participant will walk 4 meters as quickly as possible.
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Hand grip strength
Description: At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will squeeze a machine called a hand-held dynamometer 3 times with all their strength.
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: CNS Vital Signs
Description: At visits 3, 6, and 12 months following hospitalization (Cohort A - Long-term Outcomes Cohort):~The participant will sit at a computer and follow the prompts on the screen. This test takes about 45 minutes.
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Muscle Ultrasound
Description: At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo ultrasound on the quadriceps muscle on the dominant side of their body.
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Muscle Strength
Description: At visits 3, 6, and 12 months following hospitalization (Long-term Outcomes Cohort):~A dynamometer will be used to measure muscle strength in the dominant leg.
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Spirometry
Description: At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip placed on their nose and will be given a plastic mouthpiece that is connected to a machine called a spirometer. They will place their lips tightly around the mouthpiece and take in as big and deep of a breath as possible and then blow out as hard and fast as they can.
Study NCT06521502 — intervention group
Intervention type: OTHER
Intervention: Lung Diffusion Testing (DLCO)
Description: At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will have a clip on their nose. They will put their mouth over a mouthpiece that is attached to a machine. This machine will deliver a small amount of carbon dioxide when they breathe in and will also record the results of the test. They will then take a few normal breaths. Next they will inhale deeply and exhale completely. They will breathe in quickly through their mouth and hold their breath for 10 seconds or as long as they can. Then they will breathe out.
Study NCT06521502 — intervention group
Intervention type: RADIATION
Intervention: Chest CT Scan
Description: At a visit 12 months following hospitalization (Long-term Outcomes Cohort):~The participant will undergo a Chest Computed Tomography (CT) scan which uses special X-ray equipment to take detailed pictures of the lungs.
Study NCT05352139 — intervention group
Intervention type: PROCEDURE
Intervention: Resection (removal) of the degenerative tissue using the Hydrocision TenJet system
Description: During the procedure, the TenJet device will remove degenerative tendinopathic tissue using pressurized saline without causing harm to the healthy tendon fibers.
Study NCT05352139 — intervention group
Intervention type: DEVICE
Intervention: Hydrocision Tenjet System
Description: The TenJet system will be used during surgery to remove the damaged tissue from the joint
Study NCT06155045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Carbo-dissection Technique
Description: This technique comes the C02 blower with electrocautery. Thereby, producing vasodilatation due to the gas and dissection aided by the electrocautery.
Study NCT06155045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Arm
Description: This technique uses only the electrocautery as conventional model
Study NCT05855200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study NCT05855200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPEOX
Description: CAPEOX will be administered.
Study NCT05855200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX will be administered.
Study NCT06084572 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: FSSG \& BEDQ
Study NCT04911660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: 1 empagliflozin 25 mg capsule per day for 14 days
Study NCT04911660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: 1 empagliflozin 25 mg capsule per day for 14 days
Study NCT04911660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule per day for 14 days
Study NCT04911660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule per day for 14 days
Study NCT05388201 — intervention group
Intervention type: OTHER
Intervention: N95
Description: 3M N95 Respirator
Study NCT05388201 — intervention group
Intervention type: OTHER
Intervention: KN95
Description: KN95 Mask (with and without clip)
Study NCT05388201 — intervention group
Intervention type: OTHER
Intervention: KF94
Description: KF94 Mask (with and without clip)
Study NCT05388201 — intervention group
Intervention type: OTHER
Intervention: Surgical
Description: Surgical Mask (with and without clip)
Study NCT06568718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bovhyaluronidase azoximer
Description: Longidaze 3000 IU intramuscularly once every 5 days with a course of 5 injections; Longidaze 3000 IU rectal suppositories once every 3 days with a course of 10 applications; Longidaze 3000 IU rectal suppositories once every 7 days with a course of 10 applications.
Study NCT06568718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: Tamsulosin 0.4mg per os every day
Study NCT06568718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin
Description: Tamsulosin 0.4mg per os every day
Study NCT05030922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiatherogenic diet
Description: Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance
Study NCT04496609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation and automated rehabilitation / automated rehabilitation
Description: Stimulation and automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
Study NCT04496609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated rehabilitation / Stimulation and automated rehabilitation
Description: Automated rehabilitation for 40 working days, then washout during 30 days, then automated rehabilitation for 40 working days
Study NCT06526884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Next Day Clinic
Description: A dedicated Next Day Clinic team consisting of a clinician and nurse case manager will provide care and specialist referrals to patients within 24 hours of an ED visit that would have resulted in hospitalization without this novel hospital avoidance initiative.
Study NCT05728216 — intervention group
Intervention type: OTHER
Intervention: Dynamic full-field optical coherence tomography analysis of kidney biopsy
Description: Dynamic full-field optical coherence tomography analysis of kidney biopsy in the nephrology department before conventional histopathological analysis
Study NCT06326112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: o.5 mg/kg bid or tid IV
Study NCT06326112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone Tablets
Description: Diuretic as needed
Study NCT05089539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor-Neprilysin Inhibition
Description: Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
Study NCT05089539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
Study NCT05585333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MLS laser
Description: Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
Study NCT06486545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection；Paclitaxel For Injection (Albumin Bound)
Description: Liposomal irinotecan, intravenous infusion 90min, d1:~Grade 1:50mg/m2； Grade 2:60mg/m2； Grade 3:70mg/m2；~Albumin-paclitaxel, 150mg/m2, intravenous infusion, d1~DLT was observed for 2 weeks (the first cycle). The same subject received only one dose of liposomal irinotecan during the study. If the patient volunteers and the investigator determines that the benefits of continuing the original regimen outweigh the risks, the subject may continue to receive treatment for metastatic disease. The drug was repeated every 2 weeks for up to 6 cycles, and the albumin paclitaxel or liposomal irinotecan were withdrawn according to the patient's adverse reactions and physical status, and the remaining single-agent maintenance therapy was performed. Until there is a possibility of surgery, disease progression, intolerable toxicity or the patient withdraws informed consent (whichever comes first).
Study NCT06040697 — intervention group
Intervention type: DEVICE
Intervention: Thermal Anisotropy
Description: Usability assessment observation.
Study NCT04620434 — intervention group
Intervention type: DEVICE
Intervention: Video laryngoscopic view
Description: The glottic view on the screen of the video laryngoscope during laryngoscopy with a C-MAC video laryngoscope, which installed with Macintosh blade.
Study NCT04620434 — intervention group
Intervention type: DEVICE
Intervention: Direct laryngoscopic view
Description: The glottic view evaluated by the anesthesiologist who performing tracheal intubation, by direct laryngoscopy with C-MAC installed with Macintosh blade.
Study NCT05012592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Awareness Program TO Reduce Malnutrition and Helminth Infestation among Primary School children
Description: This interventional study period started from September 2021 up to September 2022 (13 months) by school nurses to implement HAPSC. After completing four to five months of the educational session the school nurse will collect midline follow-up data and the endline data will be collected at the end of the interventional study. In this period a total of nine months (except annual leave) will be considered an interventional education period. The intervention group will receive one educational session per week every month. School nurses will be assigned for each class to provide health education. Each session will be conducted for a maximum of 45 minutes. The community worker will be assigned to assist the school nurse and they will communicate with the child's parents about their child's healthy nutrition and good hygiene practice. The significance of healthy eating and hygiene behavior for the children will be shared with the child's parents or guardians properly.
Study NCT06107127 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STOP
Description: Using their symptomatic arm participants will be asked to push against a fixed force dynamometer (hand held force gauge), starting with a low level of effort and gradually increasing their effort stopping either at the point that they start to feel pain or when they feel they have pushed as forcefully as they can.
Study NCT05042622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytokine adsorber filter
Description: • Intervention group #1 a cytokine adsorber will be used (30 patients): patients on ECMO - subgroup A; septic patients - subgroup B.
Study NCT05042622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal hemoperfusion cartridge
Description: • Intervention group #2 an extracorporeal hemoperfusion cartridge will be used (30 patients): patients on ECMO - subgroup C, septic patients - subgroup D.
Study NCT05455567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA
Description: Choriocapillary vessel density calculated with OCTA
Study NCT06388265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trifold information
Description: Additional detailed and written information about the procedure will be given to the participants
Study NCT06328959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent oro-esophageal tube feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT06328959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gastric tube feeding
Description: In PNG group, disposable gastric tubes were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT04727580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10mg Q2W
Description: HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12
Study NCT04727580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 25mg Q2W
Description: HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Study NCT04727580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12
Study NCT06440668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pain Management Workshop with Non-Pharmacological Therapies
Description: 1st Session: Welcome. Expectations. Pathophysiological mechanism of pain. Influence of emotions on pain intensity. Activities: My limiting beliefs; Affirmations in front of the mirror; Mental analgesia. / 2nd: Pain and its impact on the patient's life. Forgiveness and self-forgiveness. Ho'oponopono technique. Self-esteem. Activities: Labels that limit us; Reading When I Loved Myself for Real; Self-healing meditation; Life purpose. / 3rd: Tips to slow down aging. Promotion of healthy habits; Metta meditation; Motivation for change. / 4th: Active participation in my own healing. How to face illness. Creative visualization. Activity:Energy wheel. / 5th: Review of the tools. Resolving doubts. Workshop evaluation and scales. Guide with the tools presented. Activities: Final farewell. / At the end of each session, the homework assignments are explained, and at the beginning of the next, they are reviewed. Sessions 2, 3, 4 5: Experience of a previous workshop patient.
Study NCT05269316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP9064
Description: IMP9064 Monotherapy administered for 21 days
Study NCT04275232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic plasma aliquots, a source of plasminogen
Description: Plasma eye drops, a source of plasminogen
Study NCT05577052 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Metastatic vertebrae treated with SBRT
Description: High-dose SBRT treatment
Study NCT05577052 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Metastatic vertebrae treated with SBRT
Description: High-dose SBRT treatment
Study NCT04984642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: have OGTT,normal diet, high fat diet, low calorie diet, and ketogenic diet in turn
Study NCT05733429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye cervical re-education
Description: patients will receive eye-cervical re-education in the form of 10 exercises at three phases; the first phase will include stimulation of ocular mobility, the second phase will consist of Cervical mobility exercise with restricted eye movement and the third phase will include stimulation of eye and neck movement co-ordination
Study NCT05155436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg
Description: Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
Study NCT06165705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CureSight
Description: dichoptic therapy with anaglyph goggles and eye tracking
Study NCT05450289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil
Description: In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.
Study NCT05450289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allergen Specific Immunotherapy
Description: In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
Study NCT05450289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allergen Specific Immunotherapy
Description: In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.
Study NCT05450289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard pharmacotherapy
Description: Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
Study NCT05450289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard pharmacotherapy
Description: Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
Study NCT06663579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fathers who practicing kangaroo care
Description: The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.
Study NCT06663579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fathers who not practicing kangaroo care
Description: The control group (n=28) It consists of fathers of babies practicing Kangaroo Care with their mothers in the neonatal intensive care unit.
Study NCT06663839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological NILK-2301
Description: Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.